U.S. Physical Therapy (USPH) opened 2026 with Q1 revenue of US$196.3 million and basic EPS of a loss of US$0.12, as net income excluding extra items came in at a loss of US$1.8 million. Over the past year, the company has seen quarterly revenue move from US$181.9 million in Q1 2025 to the current US$196.3 million. Over the same period, basic EPS shifted from US$0.80 a share to a loss of US$0.12, and trailing twelve month EPS was US$0.51 on net income of US$7.7 million. These figures may prompt investors to focus closely on how compressed margins are influencing the current earnings profile.

See our full analysis for U.S. Physical Therapy.

With the headline numbers on the table, the next step is to see how this margin picture aligns with widely followed narratives around U.S. Physical Therapy's growth potential and risk profile.

Margins Squeezed as Net Margin Slides to 1%

• Trailing twelve month net income is US$7.7 million on US$787.7 million of revenue, which works out to a 1% net margin compared with 4.7% last year.
• Critics highlight that this bearish concern about weaker profitability is echoed in the shift from US$32.8 million of trailing net income a year ago to US$7.7 million now and argue that such compression puts more pressure on each new dollar of revenue.
  • The move in trailing basic EPS from US$2.17 to US$0.51 over the same periods lines up with that view and keeps the focus on how efficiently the business converts sales into earnings.
  • At the quarterly level, net income excluding extra items went from US$12.1 million in Q1 2025 to a loss of US$1.8 million in Q1 2026, which also feeds into the cautious, more bearish narrative around margins.

Revenue Near US$788 Million, Forecast Growth at 7.3%

• On a trailing basis, revenue is US$787.7 million, and analysts expect about 7.3% annual revenue growth compared with a 11.4% figure cited for the wider US market.
• Supporters of a more bullish angle point out that having revenue close to US$800 million with forecasts for further growth can still underpin the business case even while margins are tighter. However, the data here show that trailing EPS at US$0.51 is far below the US$2.38 level seen at the 2025 Q3 LTM mark.
  • What stands out for that bullish stance is that revenue on a trailing basis has risen from US$664.4 million at 2024 Q4 LTM to US$787.7 million now, so top line scale is larger even if profit conversion has been weaker.
  • At the same time, the step down in trailing net income from US$36.0 million at 2025 Q3 LTM to US$7.7 million now gives bears concrete figures to point to when they question how much of that forecast growth will show up in shareholder earnings.

High 117.2x P/E Versus DCF Fair Value of US$155.63

• The stock trades around US$59 with a trailing P/E of 117.2x, compared with peer and industry averages of 16.7x and 22.4x, while a DCF fair value of US$155.63 in the analysis is well above the current share price.
• Supporters of the more bullish narrative argue that forecast earnings growth of about 56.2% per year helps explain why a DCF model points to a fair value far above US$59. However, the very high trailing P/E and a dividend yield of 3.12% that is not well covered by earnings give skeptics specific numbers to question.
  • Compared with the 1% trailing net margin and the US$7.7 million of trailing net income, a 117.2x P/E is far richer than the 16.7x and 22.4x benchmarks, which critics see as a sign that the market already prices in better future results.
  • At the same time, the gap between the US$59 share price and the US$155.63 DCF fair value estimate is what bullish investors point to when they say high implied growth in the cash flow model has not yet been reflected in the market price.

To see how other investors are interpreting this combination of compressed margins, premium P/E, and a DCF fair value well above the current share price, check out the community view on U.S. Physical Therapy Curious how numbers become stories that shape markets? Explore Community Narratives.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on U.S. Physical Therapy's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With mixed views across growth, margins, and valuation, sentiment around U.S. Physical Therapy is clearly split. Act while the data is fresh and form your own stance by weighing both the downside flags and the upside potential highlighted in the 3 key rewards and 3 important warning signs.

See What Else Is Out There

U.S. Physical Therapy is working with compressed margins, a very high 117.2x P/E, and earnings that do not comfortably cover its dividend.

If those pressure points concern you, compare this setup with companies that feature steadier income and payouts using the 12 dividend fortresses before you commit fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.